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ABSTRACT 
The liver is famous for its strong regenerative capacity, employing different modes of regeneration according to 
type and extent of injury. Mature liver cells are able to proliferate in order to replace the damaged tissue allow-
ing the recovery of the parenchymal function. In more severe scenarios hepatocytes are believed to arise also 
from a facultative liver progenitor cell compartment. In human, severe acute liver failure and liver cirrhosis are 
also both important clinical targets in which regeneration is impaired, where the role of this stem cell compart-
ment seems more convincing. In animal models, the current state of ambiguity regarding the identity and role of 
liver progenitor cells in liver physiology dampens the enthusiasm for the potential use of these cells in regenera-
tive medicine. The aim of this review is to give the basics of liver progenitor cell biology and discuss recent re-
sults vis-à-vis their identity and contribution to liver regeneration. 
 
 
THE BASICS OF HEPATIC 
STEM/PROGENITOR CELL BIOLOGY 
The liver has the amazing potential to re-
generate when mild liver damage occurs. 
During this process, remnant resting hepato-
cytes will re-enter the cell cycle and effi-
ciently replenish the liver through prolifera-
tion. A good example of the capacity of adult 
hepatocytes and bile epithelial cells to prolif-
erate is seen during recovery from partial 
hepatectomy in rats and mice, when two-
third of the liver is removed (Fausto et al., 
2012; Russo et al., 2011). More importantly, 
this capacity is underlined by the ability to 
perform living-donor liver transplantation, 
where each half is capable of re-growing to 
support different individuals. During persis-
tent and severe liver damage, hepatocytes no 
longer have the capacity to proliferate 
whereas hepatic stem/progenitor cells 
(HSPCs) are induced to expand, also known 
as a ductular reaction, oval cell reaction or 
oval cell hyperplasia. HSPCs exist in the 
smallest and most peripheral branches of the 
biliary tree, the ductules and canals of He-
ring (Kuwahara et al., 2008; Theise et al., 
1999) (Figure 1A). Their niche is composed 
mainly of hepatic stellate cells, endothelial 
cells, Kupffer cells and a specific network of 
extracellular matrix (ECM) that retains all 
molecules secreted by the niche cells 
(Lorenzini et al., 2010; Russo et al., 2011; 
Van Hul et al., 2009, 2011). Because of their 
self-renewal capacity, high proliferative abil-
ity and differentiation potential toward 
hepatocytes and cholangiocytes, HSPCs are 
considered as an attractive alternative source 
for liver cell therapy (Cantz et al., 2008; Dan 
and Yeoh, 2008). 
Browsing of the literature describing the 
origin, fate and potential of HSPCs shows 
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Figure 1: The niche of HSPCs and their expression markers  
(A) HSPCs are located in the smallest and most peripheral branches of the biliary tree, the ductules 
and canals of Hering. In healthy murine livers, canals of Hering are present in the portal area and con-
sist of one hepatocyte and several cholangiocytes/HSPCs. By immunohistochemistry, cholangio-
cytes/HSPCs are identified by their Krt19-positivity (brown). Corresponding channels and their lumens 
are magnified in the lower panels (colored squares, yellow arrowheads indicate the lumen). (B) 
HSPCs can be isolated directly using FACS or MACS with antibodies directed to EpCAM, MIC1C3, 
CD133 or using a functional assay (ALDH1A1 (aldehyde activity), MRP1 (Side Population). When 
studying their functionality, lineage tracing of quiescent HSPCs is often used based on markers such 
as OPN, SOX9, CK19, HNF1β. Once activated, HSPCs become transit amplifying cells expressing the 
surface marker (TROP2) as well as Foxl1 and LGR5 which are also used for lineage tracing. 
 
 
that investigators use different terms and ab-
breviations to describe the phenomenon of 
this liver cell type that has the above men-
tioned characteristics. Due to abbreviations 
and names such as oval cells, liver progeni-
tor cells (LPCs), liver stem cells (LSCs), 
atypical ductal cells (ADCs), or intermediate 
hepatobiliary cells, it is sometimes difficult 
to deducewhether researchers are studying 
the same cell. While it is desirable to come 
to a nomenclature and classification of these 
–maybe different- cells, in this review we 
will use the term HSPCs to encompass the 
various liver stem/progenitor cell popula-
tions irrespective of species or injury model. 
 
MODELS TO STUDY HSPCS 
Liver regeneration can be broadly char-
acterized into hepatocellular or biliary regen-
eration, which is dependent on the type of 
injury. Adaptive, but flexible crosstalk be-
tween the microenvironment (i.e. extracellu-
lar matrix (ECM) and neighboring cells, like 
Kupffer cells, myofibroblasts and hepatic 
stellate cells) and the stem-cells themselves 
are required to allow the activation of 
HSPCs (Boulter et al., 2013). Different liver 
injury mouse models have been used to 
study this HSPC activation. Two commonly 
used diets, DDC (3,5-diethoxycarbonyl-1,4-
dihydrocollidine) and CDE (choline-defi-
cient, ethionine-supplemented), are em-
ployed to activate HSPC expansion and dif-
ferentiation to hepatocytes or cholangio-
cytes. Indeed, the DDC diet results in an ac-
cumulation of protoporphyrin in hepatocytes 
leading to cholangitis (Fickert et al., 2007; 
Preisegger et al., 1999) whereas CDE re-
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solves in hepatic damage with HSPC expan-
sion (Akhurst et al., 2001). Additional possi-
bilities, like the use of a Methionine-choline-
deficient (MCD) diet (Rinella et al., 2008), 
intoxication by N-acetyl-p-aminophenol 
(APAP) (Kofman et al., 2005) or the N-2-
acetylaminofluorene (2-AAF) treatment in 
combination with 70% hepatectomy (mainly 
in rats) (Santoni-Rugiu et al., 2005) are also 
frequently used to study HSPCs. In addition 
to the different methods used to stimulate 
HSPC proliferation/differentiation, research-
ers use different isolation procedures or 
transgenic lineage tracing markers making it 
virtually impossible to compare all the dif-
ferent experimental setups. The importance 
of careful extrapolation between individual 
species  and the nature of the toxin-induced 
liver damage treatment was already high-
lighted in 2007 by a study of Jelnes and col-
laborators, showing remarkable phenotypic 
discrepancies exhibited by the progenies of 
the HSPCs in stem cell-mediated liver re-
generation models between rats and mice. 
They used CK19-positivity (and additional 
markers, like AFP, MPK, and ABCG2) to 
evaluate the HSPC activation in different 
injury models and concluded that the CDE 
model is the most appropriate model to study 
this phenomenon and that C57Bl6 mice re-
spond better than Fisher 344 rats (Jelnes et 
al., 2007). Whether the same HSPC is acti-
vated differently due to the different nature 
of the injury or whether from the beginning 
different HSPC niches exist, which can be 
independently activated depending on the 
nature of the injury, are questions that large-
ly remain unanswered. 
 
CHARACTERIZATION OF HSPCS 
While the notion of HSPCs is widely ac-
cepted, many questions remain regarding 
their characteristics. This is partly due to the 
fact that specific markers for quiescent 
HSPCs still need to be discovered. On the 
other hand, several proteins or activities that 
discriminate the HSPCs from their surround-
ing cells exist; EpCAM- (Epithelial cell ad-
hesion molecule, aka TROP1/ TACSTD1 
(Yovchev et al., 2008)), Prom1- (Prominin1, 
aka CD133 (Rountree et al., 2007)) and 
MIC1-1C3- (macrophage inhibitory cyto-
kine-1-1C3 (Dorrell et al., 2011)) antibodies 
or a combination of them, have been used to 
enrich these cells, while activities that are 
enhanced in HSPCs like efflux transporter 
activity (e. g. Side population technique 
(Govaere et al., 2014) or aldehyde dehydro-
genase activity (Dollé et al., 2012)) are more 
intricate but can also be used to isolate 
HSPCs (Figure 1B). Typically cells isolated 
by means of one of the above procedures are 
further characterized in vitro for their cell 
renewal and differentiation capacity or in 
vivo for their ability to repopulate an injured 
liver with HSPC-derived hepatocytes and 
cholangiocytes (Figure 2). 
The problem with the aforementioned 
markers is that they are also expressed on 
regular biliary epithelial cells. The current 
view is that, once awakened by signals from 
the surrounding liver tissue, HSPCs become 
transit amplifying cells expressing some pro-
teins not expressed by regular biliary epithe-
lial cells such as Foxl1 (Forkhead Box l1), 
TACSTD2/Trop2 (Tumor-associated calci-
um signal transducer 2) or LGR5 ((leucine-
rich-repeat-containing G protein-coupled re-
ceptor 5) (Huch et al., 2013; Okabe et al., 
2009; Sackett et al., 2009). Foxl1 and LGR5 
transgenic mice have been successfully used 
to isolate these transit-amplifying cells from 
injured livers for further expansion and char-
acterization, but have not been compared 
with each other yet. We are not aware of 
TACSTD2 transgenic mice, which would 
allow the comparison between Foxl1, LGR5 
and TACSTD2 expressing cells from mice 
exposed to similar injuries with respect to 
their activation-, differentiation- and prolif-
eration potential. To carry out such a study 
in one lab would require quite some re-
sources, but could reveal whether we can 
actually compare results obtained using dif-
ferent HSPC lineage tracing markers.  
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Figure 2: Regulation of HSPCs in vivo and in vitro  
In healthy livers, mature cells can autonomously replenish their hepatic compartment without interven-
tion of HSPCs. Upon injury in rodent, artificially induced by specific diets (like DDC or CDE), HSPCs 
get activated resulting in their expansion, propagation in the parenchyma and potentially to liver repair. 
Many known cytokines and growth factors (like TWEAK, FGF7, TNFα, IL-6 or IFNγ) are partially re-
sponsible for their activation. Depending on the injury (cholangiocytic vs hepatocytic), transient ampli-
fying cells (TACs) differentiate toward hepatocytes during DDC diet with the help of Wnt and HGF sig-
naling. When CDE injury occurs, TACs preferentially differentiate into cholangiocytes using Notch1 
signalization. Isolated HSPCs/TACs can be placed in culture dishes for in vitro expansion or differenti-
ation toward cholangiocyte-/hepatocyte-like cells (bipotentiality) or can be transplanted to study their 
function in vivo in uPA-SCID (urokinase-type plasminogen activator-Severe combined immunodefi-
ciency), FAH (Fumarylacetoacetase hydrolase) and FRG (FAH/Rag2/II2rg). The potential lineage con-
version of hepatocytes to cholangiocytes and YAP-dependent transdifferentiation of hepatocytes to 
HSPC-like cells is indicated by grey arrows.  
 
 
HSPCS SIGNALING PATHWAYS 
Understanding the signaling pathways 
that are involved in HSPC maintenance, ac-
tivation and differentiation are of great inter-
est to those working in the field of liver re-
generation. Not only can these pathways po-
tentially steer the in vitro culture/expansion 
of HSPCs but it could also give clues on how 
to direct these cells in injured livers to per-
haps contribute to liver regeneration. In-
flammatory cytokines play an important role 
in HSPC response. The first cytokine de-
scribed that has an explicit impact on HSPCs 
is tumor necrosis factor (TNF)-like weak in-
ducer of apoptosis (TWEAK), which is pro-
duced by monocytes, T lymphocytes and 
macrophages whose expression increases in 
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contexts of acute injury, inflammatory dis-
ease and cancer. The expression of its recep-
tor Fn14, normally expressed by epithelial 
and mesenchymal cells, is also relatively low 
in healthy tissue but is dramatically induced 
in injured and diseased tissue, such as in liv-
ers following a DDC treatment. HSPC acti-
vation by DDC was significantly reduced in 
Fn14-null mice and by the use of an anti-
TWEAK antibody while overexpression of 
TWEAK in hepatocytes (Jakubowski et al., 
2005) or exogenous TWEAK administration 
leads to periportal oval cell hyperplasia (Bird 
et al., 2013). Recently, Miyajima’s group 
found evidence that FGF7-dependent HSPC 
activation effectively contributes to progeni-
tor-dependent liver regeneration and survival 
in severe liver injury (Takase et al., 2013). 
Indeed, FGF7 expression was induced con-
comitantly with a HSPC response in the liver 
of mouse models (such DDC, CBDL), as 
well as in the serum of patients with acute 
liver failure corroborating earlier data (Dezso 
et al., 2007; Murakami et al., 2011; Steiling 
et al., 2004). FGF7-deficient mice exhibited 
markedly repressed HSPC expansion and 
higher mortality upon toxin-induced hepatic 
injury. Furthermore, transgenic expression of 
FGF7 in vivo led to the induction of cells 
with features of HSPCs and improved hepat-
ic dysfunction (Takase et al., 2013). Obvi-
ously it cannot be excluded that FGF7 may 
have a protective effect on damaged mature 
cells (i.e. hepatocytes and cholangiocytes) or 
even initiates transdifferentiation of damaged 
–or surrounding- hepatocytes (see below). 
Although the HSPC response in Fn14-
deficient mice was attenuated after CDE 
treatment, it was restored later on and ulti-
mately resulted in a level similar to that in 
WT mice (Tirnitz-Parker et al., 2010). Con-
trarily, in FGF7-deficient mice, HSPC acti-
vation was never induced even after long-
term liver injury (Takase et al., 2013). This 
suggests a more direct role of FGF-7 in 
HSPC induction, while that of TWEAK 
maybe rather enhancing and not necessarily 
indispensable.  
Many additional factors have been re-
ported to be involved in HSPC activation 
and probably also steer their differentiations. 
Hepatic growth factor (HGF)/c-MET and 
Epidermal growth factor (EGF)/EGF recep-
tor (EGFR) are key regulatory elements to 
determine HSPC activation and differentia-
tion. In c-MET knockout mice, HSPC re-
sponse was significantly less upon DDC in-
jury in vivo (Ishikawa et al., 2012) suggest-
ing that HGF is important for HSPC activa-
tion. On the other hand EGFR seems to be 
necessary for differentiation of HSPCs, since 
stimulation of the EGFR triggers the Notch1 
pathway resulting in cholangiocyte differen-
tiation and concomitant inhibition to the he-
patic lineage (Kitade et al., 2013). Wnt3a is 
expressed by macrophages triggered by 
hepatocyte damage (CDE diet) and subse-
quent debris engulfment, leading to the inhi-
bition of Notch in HSPCs and hepatocyte 
regeneration, while biliary damage activates 
Notch in HSPCs resulting in biliary specifi-
cation. Interestingly, the depletion of macro-
phages during hepatocellular damage results 
in Notch activation, instead of Wnt signal-
ing, thereby favoring biliary specification 
(Boulter et al., 2012, 2013). Other essential 
cytokines, like TNFα, interferon gamma 
(IFNγ), interleukin 6 (IL-6) and oncostatin 
(OSM), can also stimulate HSPC activation 
and were already described in earlier studies 
in which researchers were comparing partial 
hepatectomy versus stem cell-mediated liver 
regeneration (Knight et al., 2005; Shiojiri 
1997; Yeoh et al., 2007; Znoyko et al., 2005) 
(reviewed in (Kang et al., 2012)). 
 
ORIGIN OF HSPCS 
The origin of HSPCs is still under de-
bate. HSPCs and cholangiocytes share simi-
lar molecular markers suggesting that 
HSPCs originate from the biliary tree. It is 
still being disputed whether all cholangio-
cytes or merely a subpopulation are precur-
sors of HSPCs or whether a specialized cell 
type is the origin of HSPCs. Although places 
like intralobular bile ducts and the paren-
chymal-stromal interface have been de-
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scribed as HSPCs niches (Kuwahara et al., 
2008), the canal of Hering is the most ac-
cepted HSPC niche (Paku et al., 2001; 
Theise et al., 1999) (Figure 1A); anatomical-
ly it is the most logical area because cholan-
giocytes and hepatocytes meet each other in 
this region. During early liver development 
(E9-11), Dlk1+/EpCAM+ cells are defined as 
hepatoblasts expressing albumin and they are 
capable of differentiating into hepatocytes 
(EpCAM-/Dlk1-/Alb+/CK19-) and cholangio-
cytes (EpCAM+/Dlk1-/Alb-/CK19+) (Fausto 
et al., 2012; Tanaka et al., 2009). Only one 
study showed that HSPCs emerge from the 
progeny of the ductal plate cells. Carpentier 
and colleagues elegantly showed that when 
SOX9-Cre ERT2 ;ROSA26RYFP offspring 
were exposed to DDC- or CDE diets at 4 
weeks after birth, YFP positive cells expand-
ed which were derived from Sox9 positive 
ductal plate cells at day E15,5 (time of ta-
moxifen injection). These ductal plate de-
rived YFP positive cells co-expressed SOX9, 
OPN and other oval cell markers (Carpentier 
et al., 2011). 
 
PARTICIPATION OF ENDOGENOUS 
HSPCs IN LIVER REPAIR 
Many studies have shown the potential of 
stem cells or isolated HSPCs to rescue a 
damaged liver when HSPCs have an ad-
vantage over damaged hepatocytes in mouse 
models such as the uPA/SCID and FAH or 
FRG mouse models (Brezillon et al., 2008; 
Grompe et al., 2013) (Figure 2). Until recent-
ly, the actual contribution of endogenous 
HSPCs to the recovering liver mass was not 
well documented. Two very elegant lineage 
tracing studies using inducible OPN-Cre and 
HNF1β-Cre transgenic mice to follow the 
fate of HSPCs gave some insight. They 
demonstrated that during or after liver dam-
age, and only in the CDE diet, merely a 
small percentage of hepatocytes is derived 
from HSPCs (between 0.8-2.5 %) (Espanol-
Suner et al., 2012; Rodrigo-Torres et al., 
2014). In these reports, HSPCs did not give 
rise to hepatocytes during homeostasis or 
liver injury caused by BDL, DDC, PH and 
CCl4. This was in contrast to a later study 
that showed that lineage tracing of LGR5-
CRE positive cells yielded hepatocyte-like 
cells after one single injection of CCl4 or the 
DDC and MCDE diets (Huch et al., 2013). 
None of the studies found a contribution of 
HSPCs to hepatocyte turnover in healthy an-
imals. This compelling data has been under-
mined by several studies showing that there 
is no contribution of HSPCs in any of the 
situations described above. Instead of fol-
lowing the fate of HSPCs, the fate of hepato-
cytes in these studies is traced using either 
infection by AAV-Ttr-Cre viruses (Malato et 
al., 2011; Schaub et al., 2014) or regular 
Mx1-Cre mice (Tanimizu et al., 2014) and 
applying different liver injuries. The use of 
Adeno Associated Viruses (AAV) express-
ing Cre recombinase in a cell type-specific 
manner eliminates the use of Tamoxifen ad-
ministration and guarantees high recombina-
tion efficiency. Using this approach they 
show that there is probably no contribution 
of HSPCs but that rather the hepatocytes 
were the source of the repopulating hepato-
cytes, again in all possible injury settings. 
One can think of several explanations when 
trying to elucidate the discrepancy between 
these studies. As mentioned before, the use 
of different strains and age of the mice, inju-
ry models and technical approaches to inves-
tigate the contribution of HSPCs to hepato-
cyte regeneration makes the comparison 
more difficult. More importantly, the majori-
ty of HSPC tracing studies use Tamoxifen-
inducible Cre-lines to carry out lineage trac-
ing (Metzger, 2001; Feil et al., 2009). Sever-
al papers have highlighted some drawbacks 
of the use of this system in liver or HSPC 
tracing studies. First of all, the half-life of 
Tamoxifen in mice is rather long (T1/2=5-7 
days) (DeGregorio et al., 1989) and traces of 
the active compound can be found up to 4 
weeks in mice (Reinert et al., 2012).  If the 
liver injury is induced within this time frame 
one can expect that recombination in a small 
number of cells expressing the CRE can oc-
cur; these can be newly formed cells or cells 
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previously not expressing the transgene of 
interest. Secondly, Tamoxifen itself can in-
duce the expression of genes that are used to 
drive the CRE expression. Both shortcom-
ings are exemplified when using Sox9-
CreERT2 mice to trace biliary epithelial 
cells/HSPCs (Furuyama et al., 2011). Car-
pentier et al. (2011) showed that Tamoxifen 
injection in healthy mice induced ectopic 
Sox9 expression in hepatocytes already with-
in 18 hours, while Yanger et al. (2013) 
showed that DDC-induced liver injury in-
duces the expression of Sox9 in hepatocytes. 
Hence, the labeling observed in hepatocytes 
using Sox9-CreER T2 mice (Furuyama et al., 
2011) is likely not only due to differentiation 
of Sox9 positive biliary cells but rather 
demonstrates that hepatocytes (re-)express 
Sox9 when injured or treated with Tamoxi-
fen. Thirdly, the recombination efficiency 
achieved by the AAV8-based methods is ex-
tremely high reaching an average of  99 % 
in all injury settings according to the latest 
reports (Malato et al., 2011; Yanger et al., 
2014). The recombination efficiencies 
reached by the traditional transgenic lineage 
tracing is much lower varying from ~ 69.1 % 
in OPN- (Espanol-Suner et al., 2012), 
~ 28.7 % in Hnf1b- (Rodrigo-Torres et al., 
2014), ~ 10.5 in CK19- (Schaub et al., 2014) 
to 7 % in Sox9-CreER mouse lines (Tarlow 
et al., 2014); the first two reports show a 
contribution of HSPCs to hepatocyte repopu-
lation whereas the last two reports failed to 
show this. Perhaps a certain efficiency is 
needed in order to demonstrate a contribu-
tion of such a rare cell population. 
An alternate hypothesis that might at 
least partially explain the obtained results 
from these studies, is that the low hepatocyte 
repopulation from HSPCs is a matter of 
hepatobiliary linkage but not of massive 
hepatocyte production (Theise et al., 2013). 
In this scenario, damage of peribiliary 
hepatocytes, which are linked to the adjacent 
very small cholangiocytes (putative stem 
cells) of the Hering channel, would trigger 
HSPC activation and differentiation towards 
such a peribiliary hepatocyte. These hepato-
cytes must have a specialized surface that 
allows them to link with these tiniest cholan-
giocytes with cell adhesion molecules that 
are distinct from those required for linking to 
other hepatocytes (Gouw et al., 2011). By 
producing these adjacent hepatocytes, the 
HSPCs restore the link between hepatocyte 
canaliculi and the biliary tree, allowing for 
free bile flow. Hepatocyte repopulation is 
thus low only when compared with total 
hepatocytes mass. But if one considers the 
peribiliary, channel of Hering-associated 
hepatocytes as a specialized subcompart-
ment, then the repopulation of that subcom-
partment may in fact be quite robust (Theise 
et al., 2013). 
Another hypothesis that has been tested 
in mouse models of liver injury is that line-
age conversion leads to de novo formation of 
mature hepatobiliary cells (Figure 2). Line-
age conversion or trans-differentiation is a 
process where one mature adult cell trans-
forms into another mature adult cell 
(Michalopoulos, 2011; Suzuki, 2013). The 
hypothesis is based on observations from 
human pathology; biliary markers (Krt19, 
HNF1, HNF3, and HNF3) were detected 
in human hepatocytes in several cholangiop-
athies (Shin et al., 2011). In mice, several 
reports show that under certain conditions 
(more particularly in cholangiocytic damage 
settings), hepatocytes can adjust their cellu-
lar program to biliary epithelial cells 
(Michalopoulos et al., 2005; Sekiya and 
Suzuki, 2014; Tanimizu et al., 2014; Yanger 
et al., 2013). Two pathways implicated in 
this transition are Notch and Hippo signal-
ing. Evidence for these pathways comes 
from overexpression studies using again 
AAV-Cre transduction leading to overex-
pression of either the N-terminal intracellular 
Notch domain (NICD) (Yanger et al., 2013) 
or the Hippo effector YAP (Yimlamai et al., 
2014). Overexpression of NICD in hepato-
cytes by using AAV-TBG-Cre induced an 
“intermediate” phenotype characterized by 
coexpression of OPN, Sox9 and HNF4a 
(Yanger et al., 2013). YAP expression is 
high in the bile duct and expressed at lower 
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levels in hepatocytes under normal condi-
tions. Overexpression of constitutively active 
YAP in hepatocytes using AAV-TBG-Cre 
leads to a morphological change of hepato-
cytes into small oval cells that express K19, 
SOX9 and MIC1C3 (Yimlamai et al., 2014). 
Furthermore YAP needs Notch signaling 
since deletion of the RBP-J effector of Notch 
signaling abolishes this YAP-mediated 
transdifferentiation (Yimlamai et al., 2014). 
With respect to efficient recovery of liver 
damage and survival, lineage conversion 
does have advantages; the existence of vari-
ous cellular sources, potentially able to pro-
vide any cell-type, any time and in sufficient 
number, allows for quick recovery in situa-
tions that are critical for the survival of the 
organ (Michalopoulos 2014; Tanimizu et al., 
2014). Besides their seemingly modest - or 
no - contribution to repopulate the liver, 
HSPCs must have a function in the recover-
ing liver, such as perhaps giving instructive 
cues to surrounding niche cells or recover-
ing/dedifferentiating hepatocytes. To this 
end, modulation of the HSPC compartment 
appears a more realistic option in the treat-
ment of hepatic failure than cell transplanta-
tion, since the latter is anyway compromised 
due to the damaged / bad infrastructure of an 
injured liver that irrevocably affects the po-
tential effect of the transplanted cells. One 
can imagine that tissue regeneration may oc-
cur either by engraftment and differentiation 
of the donor cells at the site of injury or by 
paracrine mechanisms that stimulate endog-
enous HSPC pools to contribute to initiation 
of tissue repair. This hypothesis has been 
confirmed for some types of stem cells 
(Fouraschen et al., 2012; Parekkadan et al., 
2007; Woo et al., 2012; Zagoura et al., 
2012). In favor of such theory, some reports 
point out the additive value of individual or 
combined trophic factors (TWEAK, SCF, 
GM-CSF) as direct modulators of liver repair 
in mice with acute hepatic injury (Meng et 
al., 2012; Swenson et al., 2008; Tirnitz-
Parker et al., 2010). Thus far, no regenerative 
or survival signals have been attributed to 
the secretome of HSPCs. 
ENTERIC DYSBIOSIS AND HSPCs 
ACTIVATION? 
Following the acquisition of multicellu-
larity, organisms with increasing levels of 
specialized cells, tissues and organs emerged 
during evolution. To coordinate these spe-
cialized organs, long-distance interorgan 
communication networks appear to directly 
converse their states to one another. An illus-
tration is the co-evolution of the gut micro-
biota with its host in a carefully balanced 
system in which each requires the other 
(Holmes et al., 2012; Nicholson et al., 2012). 
If, however this balance is perturbed 
(dysbiosis) this potentially predisposes the 
host to a number of diseases marked by an 
aberrant common immune responses includ-
ing inflammatory bowel disease, asthma, 
obesity, liver triglyceride storage, insulin re-
sistance, metabolic syndrome and cancers 
(Cani, 2014; Zhao, 2013). The past decade 
has witnessed an explosion in studies exam-
ining the relationship between the microbiota 
and human health through the existence of 
inter-organ communication networks, in 
which gut microflora-fat tissue (Munukka et 
al., 2014) or gut microflora–liver (Fouts et 
al., 2012; Quigley et al., 2013; Yan et al., 
2011) axes are described. It is now accepted 
that gut microbiota contribute to the man-
agement of energy homeostasis, glucose me-
tabolism and inflammation-mediated meta-
bolic diseases (Cani, 2014; Serino et al., 
2014). Such studies have yielded a general 
hypothesis whereby microbiota products ac-
tivate the innate immune system to drive 
pro-inflammatory gene expression thus pro-
moting chronic inflammatory disease of the 
liver (Chassaing et al., 2014). 
Although we start to understand the pro-
cess of liver regeneration, what initiates it is 
not entirely understood. Without any doubt, 
a common determinant is inflammation, 
which is characterized by the activa-
tion/recruitment of macrophages, concomi-
tantly followed by myofibroblasts activation, 
along with the deposition of different kinds 
of extracellular matrices as supportive mate-
rial. One can imagine that deregulation of the 
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gut microbiota could contribute to the initia-
tion or differential mode of regeneration, i.e. 
HSPCs driven or not (Figure 3). Many ar-
guments emerging from the literature sup-
port a role for the gut microbiota in liver dis-
ease (for reviews see (Abu-Shanab and 
Quigley, 2010; Chassaing et al., 2014; 
Quigley et al., 2013; Schnabl, 2013; Sekirov 
et al., 2010) and the special issue of Gastro-
enterology, 146 (6) 2014):  
(i) An overarching mechanism by which 
an aberrant microbiota negatively impacts 
health is by driving chronic inflammation 
(Abu-Shanab and Quigley, 2010; Chassaing 
et al., 2014; Quigley et al., 2013; Schnabl, 
2013);  
(ii) Gut-derived endotoxins play a central 
role in the initiation of acute liver injury and 
progression to chronic liver disease 
(Chassaing et al., 2014);  
(iii) An imbalanced intestinal homeosta-
sis results in a breach of the gut barrier and 
subsequent microbial translocation (Fouts et 
al., 2012);  
(iv) Selective intestinal decontamination 
with antibiotics is beneficial for patients and 
prevents experimental liver injury (Cirera et 
al., 2001);  
(v) Mice with genetic deletions in the 
lipopolysaccharide (LPS) signaling pathway 
are resistant to experimental liver injury and 
fibrosis (Hartmann et al., 2012; Seki et al., 
2007; Yan et al., 2011);  
(vi) Transplantation of microbiota from 
diseased mice to germfree mice transfers 
some aspects of diseased phenotypes, indi-
cating that altered microbiota plays a role in 
disease establishment and manifestation 
(Chassaing et al., 2014; Sekirov et al., 2010).  
Recently, Fouts and collaborators have 
investigated dynamics of bacterial transloca-
tion and changes in the enteric microbiome 
in early stages of liver diseases (Fouts et al., 
2012). Cholestatic liver injury was induced 
by ligation of the common bile duct (CBDL) 
and toxic liver injury by injection of carbon 
tetrachloride in mice. Increased intestinal 
permeability and bacterial translocation oc-
curred one day following liver injury in both 
disease models. The qualitative changes in 
the intestinal microbiome were investigated 
and the data revealed that minor changes 
were noticed following CBDL, while CCl4 
administration resulted in a relative abun-
dance of Firmicutes and Actinobacteria 
compare with oil-injected mice (Fouts et al., 
2012). Thus, the changes in enteric microbi-
ome differ depending on the nature of the 
(induced) liver disease in mice. Since all di-
ets inducing artificially the HSPC compart-
ment (CDE, DDC, MCDE) have the obliga-
tory passage through the gut in common, one 
can imagine that these dietary treatments 
have an impact on the gut microbiota, there-
by also influencing the HSPC response (Fig-
ure 3). 
 
 
Figure 3: Enteric dysbiosis and HSPCs activation. Changes in the gut microbiota due to dietary input 
leads to alterations in the integrity of the intestinal barrier resulting in enhanced permeability and facili-
tates the translocation of bacteria or their products into the circulation. Green arrows illustrate how this 
dysregulation of the gut microbiota might influence HSPC activation. 
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IMPROVE AND FINE-TUNE THE  
IN VITRO STRATEGIES? 
Many research efforts are focused on 
ways to expand hepatocytes or have perfect 
differentiation conditions of stem cells to-
wards functional hepatocytes. Both are not 
current practice; hepatocytes in culture lose 
their functionality very quickly while stem 
cell differentiation towards hepatocytes often 
only reaches the hepatocyte-like cell level 
(Sancho-Bru et al., 2009). Current methods 
for differentiation of HSPCs involves often 
mixtures of soluble growth factors and/or 
cytokines (HGF, EGF, FGF-1/2/4/7, SCF, 
TGFα,β) (Dollé et al., 2012; Snykers et al., 
2009; Takase et al., 2013) and many addi-
tives such as, dexamethasone, sodium butyr-
ate, insulin, transferrin, nicotinamide and 
hydrocortisone (reviewed in Snykers et al., 
2009) (Figure 2). The expansion of HSPCs is 
not an easy task; cells tend to ‘spontaneous-
ly’ differentiate towards hepatic lineages, 
hampering efficient amplification while pre-
serving the HSPC features. Early work by 
the lab of Lola Reid reported on efficient 
clonogenic expansion of human adult Ep-
CAM+-HSPCs using a serum-free, defined 
medium (Kubota medium (Kubota and Reid, 
2000)). The self-renewal capacity of HSPCs 
was indicated by phenotypic stability after 
expansion for up to 150 population dou-
blings in this Kubota medium, with a dou-
bling time of 36 h, allowing expansion of 
HSPCs for 6 months (Schmelzer et al., 
2007). Currently, the culture method that 
employs organoid structures embedded in 
Matrigel in the presence of R-Spondin seems 
to be the most efficient way of expanding 
LGR5+- or MIC1-1C3+/CD133+/CD26—
HSPCs (Dorrell et al., 2014; Huch et al., 
2013). These cultures maintain a stem cell 
phenotype and allow for differentiation to-
wards hepatocytes and cholangiocytes (Huch 
et al., 2013). The recent in vivo findings, 
highlighting the importance of Wnt, Notch, 
FGF7 and Tweak signaling, have thus far not 
been extrapolated to improve in vitro differ-
entiation methods of HSPCs (or other stem 
cells) into hepatocytes.  
In vivo, HSPCs are not only influenced 
by growth factors and cytokines, changes in 
the extracellular matrix (ECM) seem to ef-
fect the proliferation and differentiation as 
well. The ECM is a complex structure made 
up of protein fibers that serve as a dynamic 
substrate that supports tissue repair and re-
generation (Baptista et al., 2011; Crapo et 
al., 2011). Changes in Collagen (Espanol-
Suner et al., 2012; Kallis et al., 2011; Van 
Hul et al., 2009) and Laminin (Lorenzini et 
al., 2010; Espanol-Suner et al., 2012) deposi-
tion clearly weigh on the proliferation and 
differentiation capacity of activated HSPCs 
in rodents and humans. Mimicking these 3D 
changes in ECM in a dish has become possi-
ble by the development of decellularization 
techniques (Badylak et al., 2009; Shupe et 
al., 2010). Uygun et al. (2010) successfully 
decellularized a recellularized liver matrix 
with primary rat hepatocytes, allowing cul-
ture for 48 hours. A parallel study using a 
similar approach reported on the efficient 
seeding and culture of human fetal liver cells 
and human umbilical vein endothelial cells 
for 7 days (Baptista et al., 2011). 
Similar decellularized matrixes also in-
creased hepatocyte differentiation of human 
fetal HSPCs when used as a coating sub-
strate for regular tissue culture plates (Wang 
et al., 2011). Clearly, if these novel tech-
niques evolve even further they might enable 
reproducible expansion and differentiation of 
HSPCs in the near future. 
 
CONCLUSION 
In these last couple of years we have 
learned much about the pathways and condi-
tions involved in HSPC activation thanks to 
sophisticated genetically modified mouse 
models. These same models are currently in 
conflict about the existence and function of 
HSPCs during liver injury and regeneration. 
Perhaps novel mouse liver injury models, 
more representative of human disease, need 
to be developed to fully unravel the exist-
ence, identity and function of HSPCs. 
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